Glaukos Corp (Glaukos) is an ophthalmic medical device company that develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as micro stent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- to moderate-open-angle glaucoma. Glaukos’ iStent is used in conjunction with cataract surgery. Glauko’s iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm’s canal. The company markets its products through a network of distributors in Germany, Canada, the UK, Australia, Brazil and Japan, among others. Glaukos is headquartered in San Clemente, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Glaukos Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- Glaukos Corp Company Overview
- Glaukos Corp Company Snapshot
- Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview
- Glaukos Corp - Pipeline Analysis Overview
- Glaukos Corp - Key Facts
- Glaukos Corp - Major Products and Services
- Glaukos Corp Pipeline Products by Development Stage
- Glaukos Corp Ongoing Clinical Trials by Trial Status
- Glaukos Corp Pipeline Products Overview
- Brillouin Scanning Microscope
- Brillouin Scanning Microscope Product Overview
- iDose Rock
- iDose Rock Product Overview
- iDose TREX
- iDose TREX Product Overview
- IOP Sensor System
- IOP Sensor System Product Overview
- iStent Infinite Trabecular Micro-Bypass System
- iStent Infinite Trabecular Micro-Bypass System Product Overview
- iStent Infinite Trabecular Micro-Bypass System Clinical Trial
- Mosaic System - Presbyopia
- Mosaic System - Presbyopia Product Overview
- Oxygen Enrichment Device
- Oxygen Enrichment Device Product Overview
- Glaukos Corp - Key Competitors
- Glaukos Corp - Key Employees
- Glaukos Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Glaukos Corp, Recent Developments
- Jun 14, 2024: Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
- May 28, 2024: Wilmington Eye Now Offering iDose TR as a New Treatment Option to Reduce Eye Pressure in Patients With Ocular Hypertension and Open-Angle Glaucoma
- Apr 03, 2024: Glaukos Receives Permanent J-Code for iDose TR (Travoprost Intracameral Implant)
- Apr 01, 2024: Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
- Mar 26, 2024: Center For Sight Implants New FDA-Approved iDoseTR Device
- Feb 29, 2024: Celanese Announces Commercial Launch of Glaukos' iDose TR (Travoprost Intracameral Implant) Using Celanese's VitalDose Ethylene Vinyl Acetate (EVA)
- Dec 20, 2023: Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
- Dec 14, 2023: Glaukos Announces FDA Approval of iDose TR (Travoprost Intracameral Implant)
- Oct 31, 2023: Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
- May 01, 2023: Glaukos Technologies featured in numerous scientific abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview
- Glaukos Corp Pipeline Products by Equipment Type
- Glaukos Corp Pipeline Products by Indication
- Glaukos Corp Ongoing Clinical Trials by Trial Status
- Glaukos Corp, Key Facts
- Glaukos Corp, Major Products and Services
- Glaukos Corp Number of Pipeline Products by Development Stage
- Glaukos Corp Pipeline Products Summary by Development Stage
- Glaukos Corp Ongoing Clinical Trials by Trial Status
- Glaukos Corp Ongoing Clinical Trials Summary
- Brillouin Scanning Microscope - Product Status
- Brillouin Scanning Microscope - Product Description
- iDose Rock - Product Status
- iDose Rock - Product Description
- iDose TREX - Product Status
- iDose TREX - Product Description
- IOP Sensor System - Product Status
- IOP Sensor System - Product Description
- iStent Infinite Trabecular Micro-Bypass System - Product Status
- iStent Infinite Trabecular Micro-Bypass System - Product Description
- iStent Infinite Trabecular Micro-Bypass System - A Prospective, Multicenter Study of the Glaukos iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects with Mild to Moderate Primary Open-angle Glaucoma
- iStent Infinite Trabecular Micro-Bypass System - A Prospective, Randomized, Controlled, Comparative Multicenter Clinical Study of Glaukos Trabecular Micro-Bypass System Model iS3 Infinite Vs. Hydrus in Adult Subjects with Primary Open-Angle Glaucoma (POAG)
- Mosaic System - Presbyopia - Product Status
- Mosaic System - Presbyopia - Product Description
- Oxygen Enrichment Device - Product Status
- Oxygen Enrichment Device - Product Description
- Glaukos Corp, Key Employees
- Glaukos Corp, Subsidiaries
- Glossary
- Glaukos Corp Pipeline Products by Equipment Type
- Glaukos Corp Pipeline Products by Development Stage
- Glaukos Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- STAAR Surgical Co
- LivaNova USA Inc
- IRIDEX Corporation (US)
